Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
(World News Science)

LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (`Verona Pharma`), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive interim data from a Phase 2 trial with its dry powder inhaler formulation of ensifentrine in chronic obstructive pulmonary disease (`COPD`) at the European Respiratory Society (`ERS`) International Congress on Sunday, September 29, 2019 at 10:15 AM CEST. These interim single dose data were first announced in March 2019 and followed by further positive results in August 2019 where all the primary and secondary lung function endpoints were met in the Phase 2 trial. The magnitude of...